{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:54:33Z","timestamp":1792814073883,"version":"4.5.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,4,29]],"date-time":"2014-04-29T00:00:00Z","timestamp":1398729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"},{"start":{"date-parts":[[2014,4,29]],"date-time":"2014-04-29T00:00:00Z","timestamp":1398729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Res"],"DOI":"10.1038\/boneres.2014.1","type":"journal-article","created":{"date-parts":[[2014,9,4]],"date-time":"2014-09-04T14:22:21Z","timestamp":1409840541000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["Osteoporosis in men: a review"],"prefix":"10.1038","volume":"2","author":[{"given":"Robert A","family":"Adler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,4,29]]},"reference":[{"key":"BFboneres20141_CR1","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1210\/jc.2011-3045","volume":"97","author":"NB Watts","year":"2012","unstructured":"Watts NB, Adler RA, Bilezikian JP et al. Osteoporosis in men: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2012; 97: 1802\u20131822.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFboneres20141_CR2","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.amepre.2009.01.013","volume":"36","author":"LS Lim","year":"2009","unstructured":"Lim LS, Hoeksema LJ, Sherin K . ACPM Prevention Practice Committee. Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice. Am J Prev Med 2009; 36: 366\u2013375.","journal-title":"Am J Prev Med"},{"key":"BFboneres20141_CR3","doi-asserted-by":"crossref","first-page":"356","DOI":"10.7326\/0003-4819-154-5-201103010-00307","volume":"54","author":"Preventive Services U.S. Task Force","year":"2011","unstructured":"Preventive Services U.S. Task Force. Screening for osteoporposis: U.S. preventive services task force recommendation statement. Ann Intern Med 2011; 54: 356\u2013364.","journal-title":"Ann Intern Med"},{"key":"BFboneres20141_CR4","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/j.1532-5415.2010.02769.x","volume":"58","author":"LA Jennings","year":"2010","unstructured":"Jennings LA, Auerbach AD, Maselli J, Pekow PS, Lindenauer PK, Lee SJ . Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture. J Am Geriatr Soc 2010; 58: 650\u2013657.","journal-title":"J Am Geriatr Soc"},{"key":"BFboneres20141_CR5","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1007\/s00198-005-2016-z","volume":"16","author":"AC Feldstein","year":"2006","unstructured":"Feldstein AC, Elmer PJ, Nichols GA, Herson M . Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporos Int 2006; 16: 2168\u20132174.","journal-title":"Osteoporos Int"},{"key":"BFboneres20141_CR6","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","volume":"352","author":"VB Shahinian","year":"2005","unstructured":"Shahinian VB, Kuo YF, Freeman JL, Goodwin JS . Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154\u2013164.","journal-title":"N Engl J Med"},{"key":"BFboneres20141_CR7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.maturitas.2010.11.003","volume":"68","author":"RA Adler","year":"2011","unstructured":"Adler RA . Management of osteoporosis in men on androgen deprivation therapy. Maturitas 2011; 68: 143\u2013147.","journal-title":"Maturitas"},{"key":"BFboneres20141_CR8","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1210\/jc.2013-2106","volume":"98","author":"AG Costa","year":"2013","unstructured":"Costa AG, Walker MD, Zhang CA et al. Circulating sclerostin levels and markers of bone turnover in Chinese-American and white women. J Clin Endocrinol Metab 2013; 98: 4736\u20134743.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFboneres20141_CR9","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.annepidem.2006.12.004","volume":"17","author":"E Bass","year":"2007","unstructured":"Bass E, French DD, Bradham DD, Rubenstein LZ . Risk adjusted mortality rates of elderly veterans with hip fractures. Ann Epidemiol 2007; 17: 514\u2013519.","journal-title":"Ann Epidemiol"},{"key":"BFboneres20141_CR10","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7326\/0003-4819-152-6-201003160-00008","volume":"152","author":"HP Haentjens","year":"2010","unstructured":"Haentjens HP, Magaziner J, Colon-Emeric CS et al. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 2010; 152: 380\u2013390.","journal-title":"Ann Intern Med"},{"key":"BFboneres20141_CR11","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.298.20.2381","volume":"298","author":"DC Mackey","year":"2007","unstructured":"Mackey DC, Lui LY, Cawthon PM et al. High-trauma fractures and low bone mineral density in older women and men. JAMA 2007; 298: 2381\u20132388.","journal-title":"JAMA"},{"key":"BFboneres20141_CR12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.bone.2003.10.001","volume":"34","author":"SC Schuit","year":"2004","unstructured":"Schuit SC, ven der Klift M, Weel AE et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 2004; 34: 195\u2013202.","journal-title":"Bone"},{"key":"BFboneres20141_CR13","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1359\/jbmr.061113","volume":"22","author":"R Burge","year":"2007","unstructured":"Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A . Incidence and economic burden of osteoporosis-related fractures in the United States, 2005\u20132025. J Bone Miner Res 2007; 22: 466\u2013475.","journal-title":"J Bone Miner Res"},{"key":"BFboneres20141_CR14","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1359\/jbmr.070315","volume":"22","author":"ND Nguyen","year":"2007","unstructured":"Nguyen ND, Ahlborg HG, Center JR, Eisman JA, Nguyen TV . Residual lifetime risk of fractures in women and men. J Bone Miner Res 2007; 22: 781\u2013788.","journal-title":"J Bone Miner Res"},{"key":"BFboneres20141_CR15","first-page":"1","volume":"59","author":"E Arias","year":"2011","unstructured":"Arias E . United States Life Tables 2007. Natl Vital Stat Rep 2011; 59: 1\u201360.","journal-title":"Natl Vital Stat Rep"},{"key":"BFboneres20141_CR16","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00198-011-1652-8","volume":"23","author":"RB Hopkins","year":"2012","unstructured":"Hopkins RB, Pullenayegum E, Goeree R et al. Estimation of the lifetime risk of hip fracture for women and men in Canada. Osteoporos Int 2012; 23: 921\u2013927.","journal-title":"Osteoporos Int"},{"key":"BFboneres20141_CR17","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198606263142605","volume":"314","author":"BL Riggs","year":"1986","unstructured":"Riggs BL, Melton LJ III Involutional osteoporosis. N Engl J Med 1986; 314: 1676\u20131686.","journal-title":"N Engl J Med"},{"key":"BFboneres20141_CR18","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1210\/jcem.83.7.4964","volume":"83","author":"CJ Rosen","year":"1998","unstructured":"Rosen CJ, Kurland ES, Vereault D et al. Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 1998; 83: 2286\u20132290.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFboneres20141_CR19","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1210\/jc.2003-032081","volume":"89","author":"I Van Pottelbergh","year":"2004","unstructured":"Van Pottelbergh I, Goemaere S, Zmierczak H, Kaufman JM . Perturbed sex steroid status in men with idiopathic osteoporosis and their sons. J Clin Endocrinol Metab 2004; 89: 4949\u20134953.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFboneres20141_CR20","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1359\/JBMR.050916","volume":"21","author":"S Khosla","year":"2006","unstructured":"Khosla S, Riggs BL, Atkinson EJ et al. Effects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment. J Bone Miner Res 2006; 21: 124\u2013131.","journal-title":"J Bone Miner Res"},{"key":"BFboneres20141_CR21","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/jbmr.287","volume":"26","author":"BA Christiansen","year":"2011","unstructured":"Christiansen BA, Kopperdahl DL, Kiel DP, Keaveny TM, Bouxsein ML . Mechanical contributions of the cortical and trabecular compartments contribute to differences in age-related changes in vertebral body strength in men and women assessed by QCT-based finite element analysis. J Bone Miner Res 2011; 26: 974\u2013983.","journal-title":"J Bone Miner Res"},{"key":"BFboneres20141_CR22","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00198-006-0254-3","volume":"18","author":"P Szulc","year":"2007","unstructured":"Szulc P, Delmas PD . Bone loss in elderly men: increased endosteal bone loss and stable periosteal apposition. The prospective MINOS study. Osteoporos Int 2007; 18: 495\u2013503.","journal-title":"Osteoporos Int"},{"key":"BFboneres20141_CR23","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1210\/jcem.86.2.7219","volume":"86","author":"SM Harman","year":"2001","unstructured":"Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR . Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab 2001; 86: 724\u2013731.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFboneres20141_CR24","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1365-2265.2012.04432.x","volume":"77","author":"G Sartorius","year":"2012","unstructured":"Sartorius G, Spasevska S, Idan A et al. Serum testosterone, dihydrotestosterone and estradiol concentrations in older men self-reporting very good health: the healthy man study. Clin Endocrinol (Oxf) 2012; 77: 755\u2013763.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"BFboneres20141_CR25","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1210\/jc.2006-0173","volume":"91","author":"HA Fink","year":"2006","unstructured":"Fink HA, Ewing SK, Ensrud KE et al. Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab 2006; 91: 3908\u20133915.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFboneres20141_CR26","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.bone.2012.08.111","volume":"51","author":"KM Wiren","year":"2012","unstructured":"Wiren KM, Zhang XW, Olson DA, Turner RT, Iwaniec UT . Androgen prevents hyogonadal bone loss via inhibition of resorption mediated by mature osteoblasts\/osteocytes. Bone 2012; 51: 835\u2013846.","journal-title":"Bone"},{"key":"BFboneres20141_CR27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00198-012-2057-z","volume":"24","author":"S Verschueren","year":"2013","unstructured":"Verschueren S, Gielen E, O\u2019Neill TW et al. Sarcopenia and its relationship with bone mineral density in middle-aged and elderly European men. Osteoporos Int 2013; 24: 87\u201398.","journal-title":"Osteoporos Int"},{"key":"BFboneres20141_CR28","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00198-010-1421-0","volume":"22","author":"CS Ryan","year":"2011","unstructured":"Ryan CS, Petkov VI, Adler RA . Osteoporosis in men: the value of laboratory testing. Osteoporos Int 2011; 22: 1845\u20131853.","journal-title":"Osteoporos Int"},{"key":"BFboneres20141_CR29","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.3899\/jrheum.110030","volume":"38","author":"E Romagnoli","year":"2011","unstructured":"Romagnoli E, del Fiacco R, Russo S et al. Secondary osteoporosis in men and women: clinical challenge of an unresolved issue. J Rheumatol 2011; 38: 1671\u20131679.","journal-title":"J Rheumatol"},{"key":"BFboneres20141_CR30","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0025-6196(11)62214-3","volume":"77","author":"LA Fitzpatrick","year":"2012","unstructured":"Fitzpatrick LA . Secondary causes of osteoporosis. Mayo Clin Proc 2012; 77: 453\u2013468.","journal-title":"Mayo Clin Proc"},{"key":"BFboneres20141_CR31","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/rheumatology\/39.12.1383","volume":"39","author":"TP Van Staa","year":"2000","unstructured":"Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C . Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000; 39: 1383\u20131389.","journal-title":"Rheumatology (Oxford)"},{"key":"BFboneres20141_CR32","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/BF03346716","volume":"34","author":"RA Adler","year":"2011","unstructured":"Adler RA, Hochberg MC . Glucocorticoid-induced osteoporosis in men. J Endocrinol Invest 2011; 34: 481\u2013484.","journal-title":"J Endocrinol Invest"},{"key":"BFboneres20141_CR33","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/acr.20295","volume":"62","author":"JM Grossman","year":"2010","unstructured":"Grossman JM, Gordon R, Ranganath VK et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arth Care Res (Hoboken) 2010; 62: 1515\u20131526.","journal-title":"Arth Care Res (Hoboken)"},{"key":"BFboneres20141_CR34","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jama.300.2.173","volume":"300","author":"GL Lu-Yao","year":"2008","unstructured":"Lu-Yao GL, Albertsen PC, Moore DF et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008; 300: 173\u2013181.","journal-title":"JAMA"},{"key":"BFboneres20141_CR35","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1158\/1078-0432.CCR-06-2086","volume":"13","author":"MR Smith","year":"2007","unstructured":"Smith MR . Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer. Clin Cancer Res 2007; 13: 241\u2013245.","journal-title":"Clin Cancer Res"},{"key":"BFboneres20141_CR36","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.clinbiochem.2012.01.024","volume":"45","author":"RA Adler","year":"2012","unstructured":"Adler RA . Laboratory testing for secondary osteoporosis evaluation. Clin Biochem 2012; 45: 894\u2013900.","journal-title":"Clin Biochem"},{"key":"BFboneres20141_CR37","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/jama.297.4.387","volume":"24","author":"JR Center","year":"2007","unstructured":"Center JR, Bliuc D, Nguyen TV, Eisman JA . Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 2007; 24: 387\u2013394.","journal-title":"JAMA"},{"key":"BFboneres20141_CR38","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11914-011-0090-z","volume":"10","author":"RA Adler","year":"2012","unstructured":"Adler RA . Secondary fracture prevention. Curr Osteoporos Rep 2012; 10: 22\u201327.","journal-title":"Curr Osteoporos Rep"},{"key":"BFboneres20141_CR39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00198-009-1033-8","volume":"21","author":"JA Kanis","year":"2010","unstructured":"Kanis JA, Johansson H, Oden A, Dawson-Hughes B, Melton LJ III, McCloskey EV . The effects of a FRAX revision for the USA. Osteoporos Int 2010; 21: 35\u201340.","journal-title":"Osteoporos Int"},{"key":"BFboneres20141_CR40","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00198-007-0362-8","volume":"18","author":"ND Nguyen","year":"2008","unstructured":"Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV . Development of a nomogram for individualizing hip fracture risk in men and women. Osteoporos Int 2008; 18: 1109\u20131117.","journal-title":"Osteoporos Int"},{"key":"BFboneres20141_CR41","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1210\/jc.2011-0385","volume":"96","author":"MF Holick","year":"2011","unstructured":"Holick MF, Binkley NC, Bischoff-Ferrari HA et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 1911\u20131930.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFboneres20141_CR42","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00198-011-1817-5","volume":"23","author":"A Moayyeri","year":"2012","unstructured":"Moayyeri A, Adams JE, Adler RA et al. Quantitative ultrasound of the heel and fracture risk assessment an updated meta-analysis. Osteoporos Int 2012; 23: 143\u2013153.","journal-title":"Osteoporos Int"},{"key":"BFboneres20141_CR43","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","volume":"343","author":"ES Orwoll","year":"2000","unstructured":"Orwoll ES, Ettinger M, Weiss S et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343: 604\u2013610.","journal-title":"N Engl J Med"},{"key":"BFboneres20141_CR44","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/jbmr.119","volume":"25","author":"ES Orwoll","year":"2010","unstructured":"Orwoll ES, Miller P, Adachi J et al. Efficacy and safety of once-yearly i.v. infusion of zoledronic acid 5 mg versus once-weekly 70 mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res 2010; 25: 2239\u20132250.","journal-title":"J Bone Miner Res"},{"key":"BFboneres20141_CR45","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/PL00004177","volume":"11","author":"PL Selby","year":"2000","unstructured":"Selby PL, Davies PL, Adams JE . Do men and women fracture at similar bone densities? Osteoporos Int 2000; 11: 153\u2013157.","journal-title":"Osteoporos Int"},{"key":"BFboneres20141_CR46","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00198-011-1822-8","volume":"23","author":"B Srinivasan","year":"2012","unstructured":"Srinivasan B, Kopperdahl DL, Amin S et al. Relationship of femoral neck areal bone mineral density to volumetric bone mineral density, bone size, and femoral strength in men and women. Osteoporos Int 2012; 23: 155\u2013162.","journal-title":"Osteoporos Int"},{"key":"BFboneres20141_CR47","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1007\/s00198-011-1632-z","volume":"22","author":"JA Kanis","year":"2011","unstructured":"Kanis JA, Bianchi G, Bilezikian JP et al. Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos Int 2011; 22: 2789\u20132798.","journal-title":"Osteoporos Int"},{"key":"BFboneres20141_CR48","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jocd.2013.08.001","volume":"16","author":"NB Watts","year":"2013","unstructured":"Watts NB, Leslie WD, Foldes AJ, Miller PD . 2013 ISCD Position Development Conference: task force on normative databases. J Clin Densitom 2013; 16: 472\u2013481.","journal-title":"J Clin Densitom"},{"key":"BFboneres20141_CR49","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1359\/jbmr.1997.12.11.1761","volume":"12","author":"AC Looker","year":"1997","unstructured":"Looker AC, Orwoll ES, Johnston CC Jr et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 1997; 12: 1761\u20131768.","journal-title":"J Bone Miner Res"},{"key":"BFboneres20141_CR50","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1002\/jbmr.55","volume":"25","author":"MG Donaldson","year":"2010","unstructured":"Donaldson MG, Cawthon PM, Lui LY et al. Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US National Osteoporosis Foundation Guidelines. J Bone Miner Res 2010; 25: 1506\u20131511.","journal-title":"J Bone Miner Res"},{"key":"BFboneres20141_CR51","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.urology.2005.07.017","volume":"67","author":"JM Bruder","year":"2006","unstructured":"Bruder JM, Ma JZ, Basler JW, Welch MD . Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy. Urology 2006; 67: 152\u2013155.","journal-title":"Urology"},{"key":"BFboneres20141_CR52","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1210\/jc.2005-0183","volume":"90","author":"SL Greenspan","year":"2005","unstructured":"Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM . Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005; 90: 6410\u20136417.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFboneres20141_CR53","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00198-009-0984-0","volume":"21","author":"RA Adler","year":"2010","unstructured":"Adler RA, Hastings FW, Petkov VI . Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX. Osteoporos Int 2010; 21: 647\u2013653.","journal-title":"Osteoporos Int"},{"key":"BFboneres20141_CR54","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s00198-009-1105-9","volume":"21","author":"RK Chaganti","year":"2010","unstructured":"Chaganti RK, Parimi N, Lang T, Orwoll E, Stefanick ML, Nevitt M . Bone mineral density and prevalent osteoarthritis of the hip in older men for the Osteoporotic Fractures in Men (MrOS) Study Group. Osteoporos Int 2010; 21: 1307\u20131316.","journal-title":"Osteoporos Int"},{"issue":"2","key":"BFboneres20141_CR55","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jocd.2013.09.008","volume":"17","author":"John T. Schousboe","year":"2014","unstructured":"Schousboe JT, Tanner SB, Leslie WD . Definition of osteoporosis by bone density criteria in men: effect of using female instead of male young reference data depends on skeletal site and densitometer manufacturer. J Clin Densitom e-pub ahead of print 23 October 2013; doi: 10.1016\/j.jocd.2013.09.008.","journal-title":"Journal of Clinical Densitometry"},{"key":"BFboneres20141_CR56","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD et al. Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344: 333\u2013340.","journal-title":"N Engl J Med"},{"key":"BFboneres20141_CR57","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/jbmr.1606","volume":"27","author":"EV McCloskey","year":"2012","unstructured":"McCloskey EV, Johansson H, Oden A et al. Denosumab reduces the risk of osteoporotic fracture in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res 2012; 27: 1480\u20131486.","journal-title":"J Bone Miner Res"},{"key":"BFboneres20141_CR58","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jocd.2011.05.015","volume":"14","author":"JA Cauley","year":"2011","unstructured":"Cauley JA, El-Hajj Fuleihan G, Arabi A et al. FRAX(\u00ae) Position Conference Members. Official positions for FRAX \u00ae clinical regarding international differences from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX \u00ae. J Clin Densitom 2011; 14: 240\u2013262.","journal-title":"J Clin Densitom"},{"key":"BFboneres20141_CR59","unstructured":"NOGG. National Osteoporosis Guideline Group (NOGG) osteoporosis guideline. Sheffield: NOGG [updated May 2013]. Available at http:\/\/www.shef.ac.uk\/NOGG\/ (accessed 24 January 2014)."},{"key":"BFboneres20141_CR60","first-page":"31","volume":"29","author":"RA Adler","year":"2012","unstructured":"Adler RA, Semla T, Cunningham F, Pogach L . The VHA male osteoporosis program: a national model for bone health. Fed Practitioner 2012; 29: 31\u201337.","journal-title":"Fed Practitioner"},{"key":"BFboneres20141_CR61","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1210\/jc.2003-031110","volume":"89","author":"JK Amory","year":"2004","unstructured":"Amory JK, Watts NB, Easley KA et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004; 89: 503\u2013510.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFboneres20141_CR62","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1001\/jama.2013.280386","volume":"310","author":"R Vigen","year":"2013","unstructured":"Vigen R, O\u2019Donnell CI, Baron AE et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013; 310: 1829\u20131836.","journal-title":"JAMA"},{"key":"BFboneres20141_CR63","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1007\/s00198-010-1185-6","volume":"21","author":"TJ Vokes","year":"2010","unstructured":"Vokes TJ, Gillen DL . Using clinical risk factors and bone mineral density to determine who among patients undergoing bone densitometry should have vertebral fracture assessment. Osteoporos Int 2010; 21: 2083\u20132091.","journal-title":"Osteoporos Int"},{"key":"BFboneres20141_CR64","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1359\/jbmr.081214","volume":"24","author":"S Boonen","year":"2009","unstructured":"Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD . Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 2009; 24: 719\u2013725.","journal-title":"J Bone Miner Res"},{"key":"BFboneres20141_CR65","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.bone.2009.12.034","volume":"46","author":"ES Orwoll","year":"2010","unstructured":"Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G . Efficacy and safety of monthly ibandronate in men with low bone density. Bone 2010; 46: 970\u2013976.","journal-title":"Bone"},{"key":"BFboneres20141_CR66","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/art.24879","volume":"60","author":"KG Saag","year":"2009","unstructured":"Saag KG, Zanchetta JR, Devolgelaer JP et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six month results. Arthritis Rheum 2009; 60: 3346\u20133355.","journal-title":"Arthritis Rheum"},{"key":"BFboneres20141_CR67","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","volume":"373","author":"DM Reid","year":"2009","unstructured":"Reid DM, Devogelaer JP, Saag K et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicenter, double-blind, double-dummy, randomized, controlled trial. Lancet 2009; 373: 1253\u20131263.","journal-title":"Lancet"},{"key":"BFboneres20141_CR68","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00198-007-0471-4","volume":"19","author":"KE Hansen","year":"2008","unstructured":"Hansen KE, Swenson ED, Baltz B, Schuna AA, Elliott ME . Adherence to alendronate in male veterans. Osteoporos Int 2008; 19: 349\u2013356.","journal-title":"Osteoporos Int"},{"key":"BFboneres20141_CR69","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1056\/NEJMoa1204061","volume":"367","author":"S Boonen","year":"2012","unstructured":"Boonen S, Reginster JY, Kaufman JM et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 2012; 367: 1714\u20131723.","journal-title":"N Engl J Med"},{"key":"BFboneres20141_CR70","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","volume":"261","author":"MR Smith","year":"2009","unstructured":"Smith MR, Egerdie B, Toriz NH et al. Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 261: 745\u2013755.","journal-title":"N Engl J Med"},{"key":"BFboneres20141_CR71","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1210\/jc.2012-1569","volume":"97","author":"E Orwoll","year":"2012","unstructured":"Orwoll E, Teglbjaerg CS, Langdahl BL et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 2012; 97: 3161\u20133169.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFboneres20141_CR72","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1210\/jc.2012-3048","volume":"98","author":"JM Kaufman","year":"2013","unstructured":"Kaufman JM, Audran M, Bianchi G et al. Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. J Clin Endocrinol Metab 2013; 98: 592\u2013601.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFboneres20141_CR73","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00198-013-2469-4","volume":"25","author":"B Abrahamsen","year":"2014","unstructured":"Abrahamsen B, Grove EL, Vestergaard P . Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate. Osteoporos Int 2014; 25: 757\u2013762.","journal-title":"Osteoporos Int"},{"key":"BFboneres20141_CR74","doi-asserted-by":"crossref","first-page":"463675","DOI":"10.4061\/2011\/463675","volume":"2011","author":"NE Cusano","year":"2011","unstructured":"Cusano NE, Costa AG, Silva BC, Bilezikian JP . Therapy of osteoporosis in men with teriparatide. J Osteoporos 2011; 2011: 463675.","journal-title":"J Osteoporos"},{"key":"BFboneres20141_CR75","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women. N Engl J Med 2001; 344: 1434\u20131441.","journal-title":"N Engl J Med"},{"key":"BFboneres20141_CR76","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","volume":"18","author":"ES Orwoll","year":"2003","unstructured":"Orwoll ES, Scheele WH, Paul S et al. The effect of teriparatide [human parathyroid hormone (1\u201334)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003; 18: 9\u201317.","journal-title":"J Bone Miner Res"},{"key":"BFboneres20141_CR77","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00198-004-1713-3","volume":"16","author":"JM Kaufman","year":"2005","unstructured":"Kaufman JM, Orwoll E, Goemaere S et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 2005; 16: 510\u2013516.","journal-title":"Osteoporos Int"},{"key":"BFboneres20141_CR78","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40265-012-0003-1","volume":"73","author":"L Mosekilde","year":"2013","unstructured":"Mosekilde L, Vestergaard P, Rejnmark L . The pathogenesis, treatment and prevention of osteoporosis in men. Drugs 2013; 73: 15\u201329.","journal-title":"Drugs"},{"key":"BFboneres20141_CR79","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bone.2012.11.018","volume":"53","author":"JM Kaufman","year":"2013","unstructured":"Kaufman JM, Reginster JY, Boonen S et al. Treatment of osteoporosis in men. Bone 2013; 53: 134\u2013144.","journal-title":"Bone"}],"container-title":["Bone Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/boneres20141.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/boneres20141","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/boneres20141.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T13:15:32Z","timestamp":1746364532000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/boneres20141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,29]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,12,23]]}},"alternative-id":["BFboneres20141"],"URL":"https:\/\/doi.org\/10.1038\/boneres.2014.1","relation":{},"ISSN":["2095-6231"],"issn-type":[{"value":"2095-6231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,29]]},"assertion":[{"value":"27 December 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14001"}}